

Dana Holzinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4794307/publications.pdf>

Version: 2024-02-01

29
papers

1,798
citations

361413

20
h-index

477307

29
g-index

29
all docs

29
docs citations

29
times ranked

2947
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Prevalence of Transcriptionally Active HPV Infection in Tumor-Free Oropharyngeal Tissue of OPSCC-Patients. <i>Frontiers in Oncology</i> , 2022, 12, 835814. | 2.8 | 2 |
| 2 | Detection of HPV16 /18 E6 Oncoproteins in Head and Neck Squamous Cell Carcinoma Using a Protein Immunochromatographic Assay. <i>Laryngoscope</i> , 2021, 131, 1042-1048. | 2.0 | 6 |
| 3 | HPV DNA genotyping, HPV E6*I mRNA detection, and p16INK4a/Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study. <i>Cancer Epidemiology</i> , 2021, 72, 101925. | 1.9 | 13 |
| 4 | Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study. <i>Cancers</i> , 2020, 12, 3567. | 3.7 | 23 |
| 5 | Role of human papillomavirus infection in the etiology of vulvar cancer in Italian women. <i>Infectious Agents and Cancer</i> , 2020, 15, 20. | 2.6 | 50 |
| 6 | Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. <i>International Journal of Cancer</i> , 2019, 145, 3436-3444. | 5.1 | 8 |
| 7 | Absence of disruptive TP53 mutations in high-risk human papillomavirus-driven neck squamous cell carcinoma of unknown primary. <i>Head and Neck</i> , 2019, 41, 3833-3841. | 2.0 | 2 |
| 8 | Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2019, 25, 7405-7412. | 7.0 | 13 |
| 9 | Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients. <i>Oral Oncology</i> , 2018, 78, 137-144. | 1.5 | 58 |
| 10 | Antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor. <i>International Journal of Cancer</i> , 2018, 142, 1361-1368. | 5.1 | 25 |
| 11 | Role of mucosal high-risk human papillomavirus types in head and neck cancers in Romania. <i>PLoS ONE</i> , 2018, 13, e0199663. | 2.5 | 20 |
| 12 | Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study. <i>European Journal of Cancer</i> , 2017, 74, 73-81. | 2.8 | 59 |
| 13 | Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, . | 6.3 | 77 |
| 14 | Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer. <i>Oral Oncology</i> , 2017, 70, 43-50. | 1.5 | 28 |
| 15 | Role of mucosal high-risk human papillomavirus types in head and neck cancers in central India. <i>International Journal of Cancer</i> , 2017, 141, 143-151. | 5.1 | 34 |
| 16 | Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 2748-2757. | 5.1 | 92 |
| 17 | Human papillomavirus 16 <sc>E</sc>6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. <i>Cancer</i> , 2017, 123, 4382-4390. | 4.1 | 67 |
| 18 | Prevalence and Determinants of Oral Human Papillomavirus Infection in 500 Young Adults from Italy. <i>PLoS ONE</i> , 2017, 12, e0170091. | 2.5 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Low prevalence of human papillomavirus in head and neck squamous cell carcinoma in the northwest region of the Philippines. PLoS ONE, 2017, 12, e0172240. | 2.5 | 14 |
| 20 | Low prevalence of HPV-driven head and neck squamous cell carcinoma in North-East Italy. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 133-140. | 4.5 | 30 |
| 21 | Mucosal alpha papillomaviruses are not associated with esophageal squamous cell carcinomas: Lack of mechanistic evidence from South Africa, China and Iran and from a worldwide meta-analysis. International Journal of Cancer, 2016, 139, 85-98. | 5.1 | 36 |
| 22 | HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Journal of the National Cancer Institute, 2016, 108, djv403. | 6.3 | 580 |
| 23 | From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treatment Reviews, 2016, 42, 24-29. | 7.7 | 71 |
| 24 | The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. International Journal of Cancer, 2015, 137, 2846-2857. | 5.1 | 169 |
| 25 | HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in HPV-based cervical cancer precursor screening. Gynecologic Oncology, 2015, 138, 676-682. | 1.4 | 7 |
| 26 | Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virology Journal, 2013, 10, 334. | 3.4 | 14 |
| 27 | Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. International Journal of Cancer, 2013, 133, 1389-1399. | 5.1 | 55 |
| 28 | Viral RNA Patterns and High Viral Load Reliably Define Oropharynx Carcinomas with Active HPV16 Involvement. Cancer Research, 2012, 72, 4993-5003. | 0.9 | 152 |
| 29 | Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. Journal of Oral Pathology and Medicine, 2011, 40, 629-635. | 2.7 | 65 |